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Identity 
Other names: ACDCR1; CGI-45; CGI45; FLJ25385 
FLJ42464; PAQR1; TESBP1A 




Eight exons spanning 17.5 kb. Transcription is from 
telomere to centromere. 
Transcription 
Transcription produces 11 different mRNAs, 10 
alternatively spliced variants and 1 unspliced form. 
There are 6 probable alternative promoters, 2 non 
overlapping alternative last exons and 8 validated 
alternative polyadenylation sites. The mRNAs appear 
to differ by truncation of the 5' end, truncation of the 3' 
end, presence or absence of 6 cassette exons, 
overlapping exons with different boundaries. 9 spliced 
and the unspliced mRNAs putatively encode good 
proteins, altogether 9 different isoforms (3 complete, 6 
partial), some containing Hly-III related proteins 
domain (Pfam) some transmembrane domains (Psort2); 
1 of the 3 complete proteins appears to be secreted. The 
remaining mRNA variant (spliced) appears not to 




Receptor for globular and full-length adiponectin 
(APM1), an essential hormone secreted by adipo-cytes 
that counteracts the effects of insulin. 
Expression 
Widely expressed. Highly expressed in adipose tissue 
and skeletal muscle. Expressed at intermed-iate level in 
brain, heart, spleen, kidney, liver, placenta, lung and 
peripheral blood leukocytes. Weakly expressed in 
colon, thymus and small intestine. We have also shown 
expression in normal and cancerous breast tissue as 
well as in other cancers such as prostate, colon, 
endometrial. It is also present in several cell lines. 
Localisation 
ADIPOR1 localizes to the plasma membrane. 
Function 
Receptor for globular and full-length adiponectin 
(APM1), an essential hormone secreted by adipo-cytes 
that acts as an antidiabetic. Probably involved in 
metabolic pathways that regulate lipid meta-bolism 
such as fatty acid oxidation. Mediates increased 
AMPK, PPARa ligand activity, fatty acid oxidation ad 
glucose uptake by adiponectin. Has some high-affinity 
for globular adiponectin but low-affinity for full-ength 
adiponectin. 
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Genomic structure of ADIPOR1. Blue boxes indicate exons. 
 
Homology 
The mouse, human, and rat Adipor1 protein 
(ADIPOR1) contains 375 amino acids. Human and 
mouse ADIPOR1 share 96.8% identity. 
Mutations 
Note 
One functional polymorphism has been described. 
Rs7539542 has been found to modulate expression of 




Adiponectin has been implicated in breast cancer. The
breast cancer cell lines MCF-7, MDB-MB-231 and 
T47D were found to express both adiponectin receptors 
ADIPOR1/ADIPOR2 (Dieudonne et al., 2006; Korner 
et al., 2007) and exposure of T47D cells to adiponecti , 
significantly inhibited their proliferation (Korner et al., 
2007). rs2232853 CT genotype (OR=1.67; 95% CI 
1.23-2.26) and the combination of rs7539542 GC 
(OR=0.59; 95% CI 0.36-0.98) and CC genotypes 
(OR=0.57; 95% CI 0.35-0.94) were significantly 
associated with breast cancer risk. The high expressing 
rs2241766 G allele (GG and GT genotypes) was 
associated with decreased breast cancer risk (OR=0.64; 
95% CI 0.49-0.83). The low expressing rs1501299 G 
allele was associated with increased breast cancer risk: 
for TG: OR=1.59; 95% CI 1.03-2.48, for GG: OR= 
1.80; 95% CI 1.14-2.85. 
Colon Cancer 
Note 
Adiponectin has also been implicated in colon cancer 
risk. rs266729 polymorphism was signi-ficantly 
associated with colon cancer risk: the RR for the 
GG/CG genotypes was rs266729 was associated with a 
reduced colorectal cancer risk: O.R. 0.73, 95% CI 
(0.53-0.99) (Kaklamani et al., 2008). 
Endometrial Cancer 
Note 
Adiponectin levels have been shown to correlate with 




Adiponectin levels have been shown to correlate with 
prostate cancer risk (Barb et al., 2007; Arisan et al., 
2009). 
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